Fresenius SE & Co. KGaA / Analyst ratings
Price targets
Analyst ratings
6 analysts rated this company in the past 90 days. The average target price is €52.00, this is a change of +8.5% compared to the current price.
-
Jefferies maintains Fresenius SE 'Buy' - target €55
NEW YORK (dpa-AFX Analyst) - After a meeting with management, analyst Jefferies maintained a "Buy" rating on Fresenius with a price target of €55. The discussion focused on the strategic and financial progress in the hospital and medical group's ongoing transformation, wrote James Vane-Tempest in an assessment released Tuesday. At Kabi, the focus is on new products and structural productivity improvements. Organic growth also remains important as a driver of capital returns./rob/gl/tav
Publication of the original study: September 15, 2025 / 1:54 p.m. / Time zone not specified in the study. First distribution of the original study: September 15, 2025 / 7:00 p.m. / Time zone not specified in the study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies raises target for Fresenius SE to 55 euros - 'Buy'
NEW YORK (dpa-AFX Analyst) - Research firm Jefferies raised its price target for Fresenius from €50 to €55 and maintained its "Buy" rating. Analyst James Vane-Tempest slightly raised his earnings per share (EPS) estimates in a report released Monday. He sees the medical device company on track for the second half of the year. For organic revenue growth, it remains at the upper end of the company's raised target range./gl/zb
Publication of the original study: September 12, 2025 / 10:46 AM / ET. First distribution of the original study: September 14, 2025 / 7:02 PM / ET.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS raises target for Fresenius to 57 euros - 'Buy'
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has raised its price target for Fresenius from €49 to €57 and maintained its "Buy" rating. The phase of rising market expectations is far from over, Graham Doyle wrote in his assessment published on Tuesday. They are likely to "do the work" for the stock./rob/ag/zb
Publication of the original study: September 1, 2025 / 7:33 PM / GMT
First distribution of the original study: September 2, 2025 / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank maintains Fresenius 'Buy' - target 52 euros
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its rating for Fresenius at "Buy" with a price target of €52. The healthcare group remains a "Top Pick," wrote Falko Friedrichs in a study published Thursday following the release of the figures. The past quarter was once again good, and as a result, the sales target was slightly raised./tih/bek
Publication of the original study: August 7, 2025 / Time not specified in study / CET
First distribution of the original study: August 7, 2025 / 8:05 a.m. / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Fresenius 'Buy' - target €49
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Fresenius after the company's earnings release, with a price target of €49. The hospital operator and pharmaceutical company exceeded consensus earnings estimates, Graham Doyle wrote in a flash assessment released Wednesday. This means a relatively low-risk earnings acceleration for the second half of the year. However, sales in the second quarter were slightly below the analyst consensus./rob/ck/tih
Publication of the original study: August 6, 2025 / 5:55 a.m. / GMT
First distribution of the original study: August 6, 2025 / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Fresenius SE 'Buy' - target 50 euros
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Buy" rating for Fresenius after the company's earnings release, with a price target of €50. James Vane-Tempest, at first glance, attested that the healthcare group had a strong second quarter. He noted in a study released Wednesday that this was roughly in line with analyst consensus. Following the announcement of a share buyback by Fresenius Medical Care, Fresenius intends to sell a portion of its FMC shares to maintain its current stake. He also mentioned the raised sales forecast for the current fiscal year./tih/bek
Publication of the original study: August 6, 2025 / 1:50 a.m. / ET
First distribution of the original study: August 6, 2025 / 1:50 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Fresenius SE at 'Buy' - target EUR 49
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Fresenius with a price target of €49. "What's rare should be valued higher," Graham Doyle wrote in his commentary on the MedTech group published Tuesday. He considers the Bad Homburg-based company a rare example where not only are market expectations for the current year low in risk, but where growth for the coming year is also largely in the bag. Doyle expects good quarterly results and believes the company will achieve the upper end of its annual targets. The shares are "unfairly" cheap./rob/ag/gl
Publication of the original study: July 21, 2025 / 10:39 PM / GMT. First distribution of the original study: July 22, 2025 / Time not specified in the study / Time zone not specified in the study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Fresenius SE at 'Buy' - target EUR 49
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Fresenius with a price target of €49. The Hessian-based company is among the companies in the European medtech sector that are seen as having the lowest risk of negative surprises, Graham Doyle wrote in his commentary published Friday following recent discussions./ag/jha/
Publication of the original study: June 19, 2025 / 2:30 p.m. / GMT
First distribution of the original study: June 20, 2025 / Time not specified in study / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies raises target for Fresenius SE to 50 euros - 'Buy'
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has raised its price target for Fresenius from €48 to €50 and maintained its "Buy" rating. Although it has slightly lowered its earnings expectations following the medical group's latest quarterly results, James Vane-Tempest wrote in his commentary published Friday, the price target is rising. He now values the stake in the dialysis company FMC at €40 per share, having increased it to reflect investor sentiment and the potential for dividends to shareholders./rob/mis/ag
Publication of the original study: May 29, 2025 / 7:41 a.m. / ET
First distribution of the original study: May 29, 2025 / 7:00 p.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Fresenius SE at 'Buy' - target 50 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Fresenius with a price target of €50. The tone at the Berenberg MedTech investor conference in Manhattan was surprisingly positive despite the adverse environment, wrote Sam England in his commentary published Thursday. Most companies are optimistic about the second half of the year and initially expect only limited financial burdens from tariffs./ag/mis
Publication of the original study: May 28, 2025 / 4:43 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Barclays raises target for Fresenius SE to 51 euros - 'Overweight'
LONDON (dpa-AFX Analyst) - British investment bank Barclays has raised its price target for Fresenius from €49.50 to €51 and maintained its rating at "Overweight." Hassan Al-Wakeel wrote this in his commentary published on Tuesday./ag/ajx
Publication of the original study: May 19, 2025 / 10:02 PM / GMT
First distribution of the original study: May 20, 2025 / 4:00 AM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg raises target for Fresenius SE to 50 euros - 'Buy'
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has raised its price target for Fresenius from €45 to €50 and maintained its rating at "Buy." Following the stock's strong start to the year, the medical group's good quarterly figures have reinforced the positive momentum, wrote Victoria Lambert in a review of the report released Friday. She also pointed to the company's continued strong balance sheet./rob/gl/ajx
Publication of the original study: May 8, 2025 / 4:18 p.m. / GMT First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS raises target for Fresenius SE to 49 euros - 'Buy'
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has raised its price target for Fresenius from €47 to €49 and maintained its rating at "Buy." The healthcare group has had a good start to the year, wrote Graham Doyle in a study released Thursday. There could be significantly more positive developments to come./rob/bek
Publication of the original study: May 7, 2025 / 5:54 PM / GMT
First distribution of the original study: May 8, 2025 / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains Fresenius' 'Buy' rating - target EUR 49
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained a "Buy" rating on Fresenius following the medical group's quarterly results, with a price target of €49. Adjusted results are above consensus estimates, while revenues are in line with them, Falko Friedrichs wrote in a response released Wednesday. Against this backdrop, the confirmed outlook appears well within reach./gl/tih
Publication of the original study: May 7, 2025 / 5:54 a.m. / GMT First distribution of the original study: Date not specified in study / Time not specified in study / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Fresenius SE at 'Buy' - target EUR 47
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has maintained its "Buy" rating for Fresenius with a price target of €47. The first quarter was very strong, wrote Christian Ehmann on Wednesday after the results. Both Kabi and Helios surprised positively./rob/ag/ajx
Publication of the original study: May 7, 2025 / 8:15 a.m. / Time zone not specified in study
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Fresenius SE 'Buy' - Target 48 euros
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Buy" rating for Fresenius with a price target of €48. James Vane-Tempest wrote on Wednesday that the Bad Homburg-based company presented strong quarterly results. This means that Fresenius largely performed in line with expectations./rob/ag/gl
Publication of the original study: May 7, 2025 / 1:55 a.m. / ET First distribution of the original study: May 7, 2025 / 1:55 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Fresenius SE at 'Buy' - target 47 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Fresenius following its first-quarter results, with a price target of €47. These should be well received by the market, Graham Doyle wrote in a study released Wednesday. The healthcare group is likely one of the few companies he rated that exceeded expectations in the first quarter./rob/bek/gl
Publication of the original study: May 7, 2025 / 5:37 a.m. / GMT. First distribution of the original study: May 7, 2025 / Time not specified in study / Time zone not specified in study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Barclays raises target for Fresenius SE to 49 euros - 'Overweight'
LONDON (dpa-AFX Analyst) - British investment bank Barclays has raised its price target for Fresenius from €43.50 to €49.00 and maintained its rating at "Overweight." The Biosimilar business is still practically free, wrote analyst Hassan Al-Wakeel in his latest assessment of the Bad Homburg-based company, published on Monday. The group's restructuring process has been impressive so far and is now entering its next phase./ag/ck
Publication of the original study: April 27, 2025 / 4:11 p.m. / GMT
First distribution of the original study: April 28, 2025 / 4:00 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Bernstein maintains Fresenius SE at 'Market-Perform'
NEW YORK (dpa-AFX Analyst) - US analyst firm Bernstein Research has maintained a "Market-Perform" rating on Fresenius with a price target of €50. With a view to a global trade war, analyst Lisa Bedell Clive examined the impact on the European medical technology sector in an assessment published Monday. Supply chains there are already quite deglobalized, at least with regard to China. However, trade volumes between Europe and the US remain significant. However, certain medical products could be exempt from tariffs./ajx/nas
Publication of the original study: April 7, 2025 / 5:37 a.m. / UTC First distribution of the original study: April 7, 2025 / 5:37 a.m. / UTC
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS raises target for Fresenius SE to 47 euros - 'Buy'
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has raised its price target for Fresenius from €40 to €47 and maintained its "Buy" rating. The Bad Homburg-based company's focus is now on value creation, not just loss prevention, wrote analyst Graham Doyle in his reassessment published Wednesday. Short-term market expectations are too low, and medium-term concerns in the biosimilars sector are unfounded./ag/gl
Publication of the original study: March 25, 2025 / 8:04 p.m. / GMT First distribution of the original study: March 26, 2025 / Time not specified in study / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies raises target for Fresenius to 48 euros - 'Buy'
NEW YORK (dpa-AFX Analyst) - Research firm Jefferies raised its price target for Fresenius from €44 to €48 following its annual results and maintained its "Buy" rating. In a study released Friday, analyst James Vane-Tempest raised his revenue estimate for the healthcare group by less than two percent, while slightly reducing his earnings per share forecast due to rising costs. The expert also pointed to the increased price target for the FMC stake.
Publication of the original study: March 20, 2025 / 3:36 PM / ET
First distribution of the original study: March 20, 2025 / 8:00 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Fresenius SE at 'Buy' - target 40 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its rating for Fresenius at "Buy" with a price target of €40. The medical group's investor relations team discussed the many moving parts of the company's annual targets during the annual European Healthcare Conference, analyst Graham Doyle wrote in a report released Wednesday. The focus was primarily on the role of the Helios Germany Performance Program and the tailwind from biosimilars. Fresenius also provided a clear update on how it assesses its future stake in the dialysis specialist Fresenius Medical Care, following its reduction on Monday./ck/la
Publication of the original study: March 5, 2025 / 2:23 PM / GMT. First distribution of the original study: March 5, 2025 / 2:23 PM / GMT.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research raises target for Fresenius SE to 47 euros - 'Buy'
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has raised its price target for Fresenius from €46 to €47 and maintained its "Buy" rating. The reason for the higher price target is that analyst Christian Ehmann revised his valuation model in the study published on Tuesday following the quarterly report and shifted the valuation horizon into the future. Regarding the reduced stake in dialysis specialist FMC to around 25 percent, he wrote: "With organic growth at the forefront and an improving balance sheet, Fresenius is positioning itself for the next phase of its strategic expansion."/ck/edh
Publication of the original study: March 4, 2025 / 8:15 a.m. / CET
First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg raises target for Fresenius SE to 45 euros - 'Buy'
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has raised its price target for Fresenius from €43 to €45 and maintained its rating at "Buy." The Bad Homburg-based company is in a solid position for 2025, wrote analyst Victoria Lambert in her review of strong quarterly results published on Monday./ag/nas
Publication of the original study: February 28, 2025 / 5:37 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank raises target for Fresenius SE to 49 euros - 'Buy'
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has raised its price target for Fresenius from €48 to €49 and maintained its "Buy" rating. After another unexpectedly strong quarter for the medical group, the stock remains one of its "top picks" in the sector, wrote analyst Falko Friedrichs in a study published Friday./edh/gl
Publication of the original study: February 28, 2025 / Time not specified in study / CET First distribution of the original study: February 28, 2025 / 08:17 / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains 'Buy' rating on Fresenius SE
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained a "Buy" rating on Fresenius with a price target of €48. The medical technology group surprised positively in the last quarter and largely met expectations with its new outlook, wrote analyst Falko Friedrichs in a review published Thursday./gl/edh
Publication of the original study: February 27, 2025 / 8:10 a.m. / CET First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Fresenius SE 'Buy' - Target 46 euros
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has maintained its rating for Fresenius at "Buy" with a price target of €46. The medical device company achieved a solid final quarter of 2024, wrote analyst Christian Ehmann in a quick assessment published Wednesday. The outlook was in line with consensus estimates./mf/edh
Publication of the original study: February 26, 2025 / 8:15 a.m. / CET
First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman leaves Fresenius SE at 'Neutral' after figures
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Fresenius at "Neutral" with a price target of €38. The hospital operator and medical group finished 2024 strongly, wrote analyst Richard Felton in a quick assessment released Wednesday./ck/gl
Publication of the original study: February 26, 2025 / 7:19 a.m. / GMT First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Fresenius SE at 'Buy' - target 40 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained a "buy" rating on Fresenius following the company's earnings release, with a price target of €40. The medical technology company's revenue and adjusted operating result (EBITDA) in the last quarter were just above consensus estimates, analyst Graham Doyle wrote in an initial reaction on Wednesday. The outlook for 2025 appears somewhat conservative, but should be received positively given the recent success story and the raised medium-term Kabi targets./gl/edh
Publication of the original study: February 26, 2025 / 6:58 a.m. / GMT First distribution of the original study: February 26, 2025 / 6:58 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Fresenius 'Buy' - target €44
NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained its "Buy" rating for Fresenius after the company's earnings release, with a price target of €44. The full year roughly met expectations, wrote analyst James Vane-Tempest in a report released Wednesday. However, investors should focus more on the raised Kabi margin target, the improved medium-term debt outlook, and the dividend. The future of the shares in Fresenius Medical Care is also likely to be a focus./tih/gl
Publication of the original study: February 26, 2025 / 1:58 a.m. / ET First distribution of the original study: February 26, 2025 / 1:58 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Fresenius SE at 'Buy' - target 40 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Fresenius with a price target of €40. US investors are rather apathetic toward European medical technology manufacturers, analyst Graham Doyle wrote in an industry report released Tuesday. The shares are now valued higher than their counterparts in the US, and at the same time, import tariffs are looming from there. Fresenius, Alcon, and Siemens Healthineers were the most frequently discussed companies in discussions with investors./bek/tih
Publication of the original study: February 10, 2025 / 5:51 PM / GMT
First distribution of the original study: February 10, 2025 / 5:51 PM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research raises target for Fresenius SE to 46 euros - 'Buy'
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has raised its price target for Fresenius from €42 to €46 and maintained its rating at "Buy." The Bad Homburg-based company is expected to present solid quarterly figures, wrote analyst Christian Ehmann in his outlook published Wednesday. However, the focus will be on growth and capital utilization in the new year./ag/mis
Publication of the original study: February 5, 2025 / 8:15 a.m. / CET
First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains Fresenius at 'Neutral' - Target 38 euros
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Fresenius at "Neutral" with a price target of €38. Analyst Richard Felton fine-tuned his estimates on Monday evening ahead of the company's quarterly results at the end of the month. He now attests to a somewhat more conservative margin outlook for the hospital group Helios for the new year due to higher costs and the discontinuation of energy subsidies in Germany./ag/tav
Publication of the original study: February 3, 2025 / 9:04 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Fresenius SE at 'Buy' - target 43 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Fresenius with a price target of €43. The Bad Homburg-based company is likely to have finished 2024 solidly, wrote analyst Victoria Lambert in her outlook for the balance sheet at the end of February, published on Monday. The strong subsidiary Kabi boosted the margin in the fourth quarter./ag/mne
Publication of the original study: January 31, 2025 / 5:33 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Fresenius SE at 'Buy' - target 43 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its rating for Fresenius at "Buy" with a price target of €43. The healthcare group is finally gaining more traction for a positive turnaround, wrote analyst Victoria Lambert in an assessment published Thursday, also with a view to the group's streamlining measures achieved in 2024./ajx/nas
Publication of the original study: January 29, 2025 / 5:44 PM / GMT First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies raises target for Fresenius to 44 euros - 'Buy'
NEW YORK (dpa-AFX Analyst) - Research firm Jefferies raised its price target for Fresenius from €40 to €44 ahead of fourth-quarter results and maintained its "Buy" rating. Analyst James Vane-Tempest raised his revenue estimate for the hospital operator and medical device manufacturer in a report released Wednesday. With a higher earnings per share estimate, he took the company's cost savings into account./bek/tav
Publication of the original study: January 15, 2025 / 3:06 PM / ET
First distribution of the original study: January 15, 2025 / 7:00 PM / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
JPMorgan maintains Fresenius at 'Overweight' - target 42 euros
NEW YORK (dpa-AFX Analyst) - US bank JPMorgan has maintained Fresenius's "Overweight" rating with a price target of €42. The challenges that would have resulted in another below-average year for shares of European medical technology companies in 2024 are likely to persist in the first half of 2025, wrote analyst David Adlington in an industry outlook published Tuesday. He sees additional risks from company-specific factors, particularly at Carl Zeiss Meditec, Elekta, and Getinge. Things could improve for some stocks in the second half of the year, particularly the attractively valued Gerresheimer and Smith & Nephew. Adlington also sees significant potential at Fresenius. The company has already achieved significant operational improvements./gl/tav
Publication of the original study: December 2, 2024 / 10:54 PM / GMT. First distribution of the original study: December 3, 2024 / 12:15 AM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Fresenius SE at 'Buy' - target 34 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Fresenius with a price target of €34. Although European medical technology stocks have underperformed the overall market this year, analyst Graham Doyle remains skeptical about the sector in general. His 2025 sales and earnings forecasts for 10 of the 17 sector stocks he covers are below consensus estimates, he wrote in an industry commentary released Tuesday. /edh/ag
Publication of the original study: November 26, 2024 / 4:08 a.m. / GMT
First distribution of the original study: November 26, 2024 / 4:08 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Barclays raises target for Fresenius SE to 40 euros - 'Overweight'
LONDON (dpa-AFX Analyst) - British investment bank Barclays raised its price target for Fresenius from €38 to €40 and maintained its rating at "Overweight." Analyst Hassan Al-Wakeel presented his 2025 outlook for the European medical technology industry on Wednesday evening. His favorites are Fresenius, Siemens Health, Convatec, and Amplifon. Like Convatec, Fresenius is a very convincing turnaround story./ag/la
Publication of the original study: November 20, 2024 / 9:48 PM / GMT
First distribution of the original study: November 21, 2024 / 5:00 AM / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research lowers target for Fresenius SE to 42 euros - 'Buy'
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research has lowered its price target for Fresenius from €44 to €42, but maintained its "Buy" rating. "Next step: revitalization," wrote analyst Christian Ehmann in his review of strong quarterly figures released on Monday. The medical group is well on its way to realignment./ag/zb
Publication of the original study: November 18, 2024 / 8:15 a.m. / CET
First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains Fresenius SE at 'Neutral' - Target 38 euros
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Fresenius at "Neutral" with a price target of €38. Analyst Richard Felton adjusted his estimates on Thursday evening in line with the Bad Homburg-based company's quarterly report./ag/gl
Publication of the original study: November 7, 2024 / 9:12 PM / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Fresenius SE at 'Buy' - target 43 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained a "Buy" rating on Fresenius with a price target of €43. The medical group's shares appear attractively valued given the company's renewed strong quarterly figures and improved earnings outlook, wrote analyst Victoria Lambert in a study published Thursday./gl/edh
Publication of the original study: November 6, 2024 / 5:34 PM / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Fresenius 'Buy' - target 43 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Fresenius following its quarterly results, with a price target of €43. The results exceeded consensus estimates, wrote analyst Victoria Lambert in an initial reaction released Wednesday. The medical technology company also raised its annual outlook./edh/tih
Publication of the original study: November 6, 2024 / 8:31 a.m. / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research maintains Fresenius SE 'Buy' - Target 44 euros
HAMBURG (dpa-AFX Analyst) - Following the company's quarterly results, the analyst firm Warburg Research maintained a "Buy" rating on Fresenius with a price target of €44. The medical device company met expectations on the sales side, while adjusted operating profit (EBIT) surprised positively, analyst Christian Ehmann wrote in an initial reaction on Wednesday. Overall, Fresenius performed very well. The group is developing in the right direction./gl/mis
Publication of the original study: November 6, 2024 / 8:15 a.m. / CET. First distribution of the original study: Date not specified in the study / Time not specified in the study / CET.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman maintains Fresenius SE at 'Neutral' - Target 38 euros
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs has maintained its rating for Fresenius at "Neutral" with a price target of €38. The strong business momentum continued in the third quarter, analyst Richard Felton wrote Wednesday morning after the company's results. The targets have been raised, but the consensus is already at the upper end of expectations./ag/gl
Publication of the original study: November 6, 2024 / 7:33 a.m. / GMT. First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Fresenius SE at 'Buy' - target 40 euros
NEW YORK (dpa-AFX Analyst) - The analyst firm Jefferies has maintained its "Buy" rating for Fresenius after the company's earnings release, with a price target of €40. Analyst James Vane-Tempest stated on Wednesday morning that the healthcare group significantly exceeded expectations with some of its key metrics. The group's forecasts for 2024 were also raised, after Fresenius had already set its operating result (EBIT) target at the upper end of the previous forecast range when presenting its half-year figures./ck/ag
Publication of the original study: November 6, 2024 / 2:12 a.m. / ET
First distribution of the original study: November 6, 2024 / 2:12 a.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
UBS maintains Fresenius SE at 'Buy' - target 34 euros
ZURICH (dpa-AFX Analyst) - Swiss bank UBS has maintained its "Buy" rating for Fresenius with a price target of €34. The medical and hospital group's third-quarter report was positive, analyst Graham Doyle wrote on Wednesday morning. However, questions are likely to arise during the conference call about how Helios Germany intends to defend its margins over the next 18 months. However, Doyle expects the group consensus to continue to rise slightly./ag/gl
Publication of the original study: November 6, 2024 / 6:56 a.m. / GMT First distribution of the original study: November 6, 2024 / 6:56 a.m. / GMT
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Jefferies maintains Fresenius SE at 'Buy' - target 40 euros
NEW YORK (dpa-AFX Analyst) - Research firm Jefferies has maintained its "Buy" rating for Fresenius ahead of third-quarter results, with a price target of €40. The market has already scaled back its expectations for the business of the hospital division Helios and the liquid medicine subsidiary Kabi, wrote analyst James Vane-Tempest in a study released Friday. The medical group Fresenius is also expected to confirm its annual targets.
Publication of the original study: October 25, 2024 / 12:30 PM / ET. First distribution of the original study: October 25, 2024 / 12:30 PM / ET.
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Warburg Research raises target for Fresenius SE to 44 euros - 'Buy'
HAMBURG (dpa-AFX Analyst) - The analyst firm Warburg Research raised its price target for Fresenius from €43 to €44 ahead of its quarterly results and maintained its rating at "Buy." The medical group should post solid key figures despite seasonal weakness at its subsidiary Helios, analyst Christian Ehmann wrote in an outlook published Friday./edh/mis
Publication of the original study: October 25, 2024 / 8:15 a.m. / CEST
First distribution of the original study: Date not specified in study / Time not specified in study / CEST
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Fresenius SE at 'Buy' - target 43 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Fresenius ahead of its quarterly results, with a price target of €43. The medical technology group is expected to report a 5 percent increase in sales and a 6 percent increase in earnings (adjusted EBIT) in the third quarter, analyst Victoria Lambert wrote in a study released Monday. Due to the sluggish summer business, the third quarter is likely to be the weakest of the year./edh/mis
Publication of the original study: October 18, 2024 / 4:31 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Deutsche Bank Research maintains Fresenius' 'Buy' rating - target EUR 42
FRANKFURT (dpa-AFX Analyst) - Deutsche Bank Research has maintained its "Buy" rating for Fresenius ahead of the company's third-quarter results, with a price target of €42. According to a study released Thursday, analyst Falko Friedrichs expects "solid results" from the medical technology group and hospital operator and a confirmation of its annual targets./ck/mis
Publication of the original study: October 17, 2024 / Time not specified in study / CET
First distribution of the original study: Date not specified in study / Time not specified in study / CET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Goldman raises target for Fresenius SE to 38 euros - 'Neutral'
NEW YORK (dpa-AFX Analyst) - US investment bank Goldman Sachs raised its price target for Fresenius from €30 to €38, but maintained its rating at "Neutral." Analyst Richard Felton raised his estimates for the Bad Homburg-based company in his commentary published Friday, reflecting the medical group's increased business momentum./ag/la
Publication of the original study: September 12, 2024 / 9:29 PM / BST
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG), Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.
-
Berenberg maintains Fresenius SE at 'Buy' - target 43 euros
HAMBURG (dpa-AFX Analyst) - Private bank Berenberg has maintained its "Buy" rating for Fresenius with a price target of €43. Medical technology companies are back on track after a weak previous year, the experts wrote in their industry commentary published on Wednesday. Their favorites for the remainder of 2024 and into the new year are Fresenius, Alcon, and Biomerieux among the large caps. Among the small caps, they are focusing primarily on Advanced Medical Solutions, Hikma, and Stratec. A reassessment is overdue at Fresenius./ag/zb
Publication of the original study: September 10, 2024 / 4:56 PM / GMT
First distribution of the original study: Date not specified in study / Time not specified in study / Time zone not specified in study
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 (1) of the German Securities Trading Act (WpHG) and Article 20 of Regulation (EU) No. 596/2014 for the aforementioned analyst firm can be found at http://web.dpa-afx.de/offenlegungspflicht/offenlegungs_pflicht.html.